What is non-HDL cholesterol — and why does it matter more than LDL?
Non-HDL cholesterol appears on every standard lipid panel. Most clinicians don't explain it. Most patients don't ask about it. And that's a gap worth closing, because non-HDL is a more complete measure of cardiovascular risk than LDL alone — and it's already sitting right there in your results.
The 30-second version
Non-HDL cholesterol = total cholesterol − HDL cholesterol.
That's it mathematically. What it represents conceptually: all the cholesterol carried inside atherogenic (plaque-forming) particles — not just LDL, but also VLDL remnants, IDL (intermediate-density lipoprotein), and lipoprotein(a). LDL-C captures most of the picture, but non-HDL captures the rest of it too.
What LDL misses
A standard lipid panel reports LDL cholesterol, which measures (or estimates) the mass of cholesterol inside LDL particles specifically. That's the dominant atherogenic lipoprotein for most people, so LDL is a reasonable starting point.
But it leaves out two relevant categories:
VLDL remnants and IDL. VLDL is produced by the liver and carries triglycerides to peripheral tissues. As VLDL is processed, it loses triglycerides and shrinks into IDL, then LDL. Along the way — as VLDL remnants and IDL — these particles are atherogenic. They can penetrate the artery wall and contribute to plaque formation. Standard LDL-C counts only the fully-formed LDL at the end of that process. VLDL cholesterol and IDL cholesterol sit in the non-HDL minus LDL gap.
Lipoprotein(a). Lp(a) carries its own cholesterol content, some of which is counted inside the LDL-C calculation and some of which appears in the non-HDL gap. This is one reason why an elevated Lp(a) can create a confusing picture — its cholesterol contribution is distributed across several calculated values rather than appearing cleanly as its own line item. See the complete Lp(a) guide for why this matters.
When the non-HDL / LDL gap is large
In most people, non-HDL minus LDL is approximately 30 mg/dL. This reflects a roughly normal amount of VLDL cholesterol in circulation — typical in someone with triglycerides in the 100–150 mg/dL range.
When the gap is larger — say, non-HDL is 40 or 50 mg/dL higher than LDL — that means excess VLDL is circulating. In practice, this almost always tracks with elevated triglycerides, which is itself a marker of metabolic patterns worth addressing: excess refined carbohydrates, excess alcohol, insulin resistance, or a combination.
A large non-HDL / LDL gap is a signal that the standard LDL number is understating the atherogenic picture. The total burden of cholesterol in atherogenic particles is higher than LDL alone implies, and the excess comes from the remnant particle category that metabolic interventions (reducing refined carbohydrates, losing weight, managing insulin resistance) specifically address.
The non-HDL target framework
Non-HDL targets in the 2026 AHA dyslipidemia guideline are set at approximately 30 mg/dL above the corresponding LDL target — because that 30 mg/dL represents the typical VLDL contribution in a metabolically healthy person:
| Risk tier | LDL target | Non-HDL target |
|---|---|---|
| Very high risk | <55 mg/dL | <85 mg/dL |
| High risk | <70 mg/dL | <100 mg/dL |
| Moderate risk | <100 mg/dL | <130 mg/dL |
| Low risk | <130 mg/dL | <160 mg/dL |
If your LDL is at target but non-HDL is above its corresponding target, the excess is coming from VLDL and remnants — usually a triglyceride-management problem, not an LDL problem.
Non-HDL versus ApoB: which is better?
Both non-HDL and ApoB are more complete than LDL alone. They capture different things.
Non-HDL is a cholesterol-mass measure. It counts more of the atherogenic cholesterol than LDL does, but it still measures mass — not particles. Two people with identical non-HDL can have different particle counts depending on particle size and composition.
ApoB is a particle-count measure. Because every atherogenic lipoprotein has exactly one ApoB-100 molecule, ApoB counts them directly. It's the most accurate single marker of atherogenic particle burden and consistently outperforms both LDL and non-HDL in head-to-head predictive studies.
The hierarchy, from most to least predictive:
- ApoB (particle count — most predictive)
- Non-HDL cholesterol (more complete mass measure than LDL)
- LDL cholesterol (standard, widely measured, most discussed)
In practice, the 2026 AHA guideline tracks all three — LDL and non-HDL as primary targets, ApoB as a refinement tool particularly for people on therapy who haven't reached LDL/non-HDL goals or who have metabolic risk factors. The lipid panel translator interprets all three together.
A practical example
Consider two people:
Person A: Total cholesterol 195, HDL 55, LDL 115, triglycerides 125. Non-HDL = 195 − 55 = 140. Non-HDL minus LDL = 25. Tight gap, normal VLDL, metabolically clean picture.
Person B: Total cholesterol 210, HDL 45, LDL 110, triglycerides 275. Non-HDL = 210 − 45 = 165. Non-HDL minus LDL = 55. Large gap, excess VLDL, elevated triglycerides signal metabolic stress. LDL alone looks almost identical to Person A. Non-HDL tells a very different story.
Person B's LDL number creates a false impression of similarity. Their non-HDL number correctly flags that something different is happening metabolically. Their ApoB would likely confirm it.
What to do if non-HDL is elevated
If your non-HDL is above target while your LDL is at or near target, the excess is VLDL-driven. The metabolic levers:
- Reduce refined carbohydrates and added sugar — the primary driver of excess hepatic VLDL production in most adults
- Reduce alcohol — alcohol raises triglycerides dose-dependently
- Lose weight if applicable — adiposity, especially visceral, drives VLDL overproduction
- Increase aerobic exercise — the most effective single behavioral intervention for lowering triglycerides and VLDL
- Check fasting glucose and HbA1c — elevated VLDL alongside elevated triglycerides often reflects insulin resistance that hasn't been formally diagnosed
If non-HDL remains above target after lifestyle changes and LDL is already at goal, fibrates or omega-3 fatty acids (at prescription doses) are the medications most specifically targeted at VLDL and triglycerides.
Use the lipid panel translator to see where all your numbers sit together, including non-HDL in context with LDL, ApoB, triglycerides, and HDL. For the LDL risk-tier framework and how non-HDL fits into it, see the complete LDL guide.
Educational resource. Not medical advice. See our methodology and citations.